NCT06175767View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 14, 2025

Primary Completion Date

July 31, 2025

Study Completion Date

September 30, 2025

Conditions
Parkinson's Disease
Interventions
DRUG

MT101-5

Tablet

Sponsors
All Listed Sponsors
lead

Mthera Pharma Co., Ltd.

INDUSTRY

NCT06175767 - A Study to Evaluate the Safety, Tolerability and Efficacy of MT101-5 in Subjects with Early Parkinson's Disease | Biotech Hunter | Biotech Hunter